NCT02787369

ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL

A Phase Ib Study of ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed Chronic Lymphocytic Leukemia

• Status: Active Not Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 3 (actual)
• Sponsor: Dana-Farber Cancer Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This research study is studying a drug called ACY-1215 in combination with ibrutinib or idelalisib as a possible treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).

Detailed description

This research study is a Phase I clinical trial. The investigators are studying the combination of the B-cell receptor (BCR) pathway inhibitors with ricolinostat, in order to try to enhance both the initial remission and to help improve the response in those who relapse after a first inhibitor and are receiving a second. The FDA (the U.S. Food and Drug Administration) has not approved ACY-1215 as a treatment for any disease. ACY-1215 or ricolinostat is a histone deacetylase inhibitor, specifically HDAC6. The FDA has approved idelalisib as well as ibrutinib as treatment options for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).

Conditions

• Recurrent Chronic Lymphoid Leukemia

Interventions

Type	Name	Description
DRUG	ACY-1215
DRUG	Ibrutinib
DRUG	Idelalisib

Timeline

• Start date: 2016-05-01
• Primary completion: 2026-04-01
• Completion: 2027-04-01
• First posted: 2016-06-01
• Last updated: 2026-01-07

Locations

1 site across 1 country: United States